Randomised phase III trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan, plus or minus celecoxib in patients with previously treated metastatic colorectal cancer.

Trial Profile

Randomised phase III trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan, plus or minus celecoxib in patients with previously treated metastatic colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DaVINCI
  • Most Recent Events

    • 07 Dec 2010 Trial location (Australia) identified as reported by Australian New Zealand Clinical Trials Registry.
    • 07 Dec 2010 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top